Nuvation Bio Inc. Stock Prediction and Forecast [NUVB]

AI-generated source summary

Nuvation Bio Inc. (NUVB) is currently ranked as a Hold/Accumulate, exhibiting a score of 0, indicating significant volatility. The stock achieved a 93.24% gain over the past 23 days since initial recommendation, with an average daily gain of 4.05%. Technical analysis shows a break through a wide and strong short-term rising trend, suggesting continued upward momentum. According to fan theory, a resistance point and potential peak is projected at $7.51. The three-month outlook anticipates a 75.19% change, with returns ranging from 12.53% to 48.26%. The 12-month analysis projects a 57.48% change, with prices potentially fluctuating between $3.88 and $7.52. On the last trading day, NUVB closed at $7.15, marking a nearly 49% increase from its opening price of $4.80, with a notable trading volume of 59 million shares ($420.02 million). The 52-week high reached $7.35, while the low was $1.54. The stock is 2.72% below its 52-week high. News surrounding the commercialization of its lung cancer drug, Ibtrozi, and positive patient enrollment reports are supportive. However, a modest institutional stake was disclosed, and insider trading activity includes a chief scientist selling 100,000 shares, balancing optimism with caution. Nuvation's pipeline advancement in high-grade IDH1-mutant glioma presents a potential long-term value driver. Expect near-term volatility driven by market metrics and options activity. The stock exhibits a negative P/E ratio of -11.26, indicating negative earnings. Support levels are identified at $5.15 and $4.48, with a critical support from accumulated volume at $5.37. Daily average volatility is 17.46%, classifying the stock risk as medium. Moving Averages show mixed signals in the short term (MACD: Sell, Short MA: Sell, Long MA: Sell), but the long-term Short MA is a Buy, and the cross between MA35/MA100 is a Buy. A buy signal was issued from a pivot bottom 39 days ago. The suggested stop-loss is $6.90 (-3.56%). Our analysis concludes that NUVB is currently overvalued and should be considered a hold candidate due to minor technical weaknesses, with an anticipated open lower by $0.670 at $6.48 on Thursday, November 20th.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   20 Nov 2025, 04:52 UTC

   The analyst published the original source item.

2. First prediction resolved

   20 Nov 2025, 18:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   20 Nov 2025, 18:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.